Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Profit After Tax (2016 - 2023)

RedHill Biopharma has reported Profit After Tax over the past 12 years, most recently at $101.2 million for Q2 2023.

  • Quarterly Profit After Tax rose 764.51% to $101.2 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $11.6 million through Jun 2023, up 122.61% year-over-year, with the annual reading at -$8.1 million for FY2025, 2344.44% down from the prior year.
  • Profit After Tax was $101.2 million for Q2 2023 at RedHill Biopharma, up from -$50.2 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $101.2 million in Q2 2023 and troughed at -$50.2 million in Q1 2023.
  • The 5-year median for Profit After Tax is -$16.6 million (2020), against an average of -$8.4 million.
  • The largest YoY upside for Profit After Tax was 764.51% in 2023 against a maximum downside of 193.17% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$11.7 million in 2019, then tumbled by 108.12% to -$24.3 million in 2020, then fell by 0.17% to -$24.4 million in 2021, then surged by 84.7% to -$3.7 million in 2022, then skyrocketed by 2815.02% to $101.2 million in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Profit After Tax are $101.2 million (Q2 2023), -$50.2 million (Q1 2023), and -$3.7 million (Q4 2022).